Furiex Pharmaceuticals (FURX) 104.00 $FURX
Premature Ejaculation - Pipeline Review, H1 2014
M2 - Mon May 12, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c22w8w/premature) has announced the addition of the "Premature Ejaculation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Premature Ejaculation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Ejaculation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Premature Ejaculation - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Premature Ejaculation and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Premature Ejaculation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Premature Ejaculation pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Profiled: - Allergan, Inc. - Ampio Pharmaceuticals, Inc. - Dong-A Socio Holdings Co Ltd - Furiex Pharmaceuticals, Inc. - NeuroHealing Pharmaceuticals Inc. - Plethora Solutions Holdings plc - SK Chemicals Co., Ltd. Drug Profiles: - tramadol hydrochloride - (lidocaine prilocaine) - dapoxetine hydrochloride - onabotulinumtoxinA - DA-8031 - IX-01 - modafinil - NCE-405 - Small Molecule for Sexual Dysfunction For more information visit http://www.researchandmarkets.com/research/c22w8w/premature
Furiex Pharmaceuticals Reports First Quarter 2014 Financial Results
Business Wire - Wed May 07, 3:05PM CDT
--Royalty revenues of $6.4 million.
Irritable Bowel Syndrome - Pipeline Review, H1 2014: 29 Companies and 37 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/tqsgh4/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Alba Therapeutics Corporation - AlbireoPharma - Alfa Wassermann S.p.A - AltheRx Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Dainippon Sumitomo Pharma Co., Ltd. - Dong-A Socio Holdings Co Ltd - Drais Pharmaceuticals, Inc. - Furiex Pharmaceuticals, Inc. - GIcare Pharma Inc - Hanmi Pharmaceuticals, Co. Ltd. - ImmusanT, Inc. - Ironwood Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. - MicroDose Therapeutx, Inc. - Ono Pharmaceutical Co., Ltd. - ProMetic Life Sciences Inc. - Protagonist Therapeutics Inc. - RaQualia Pharma Inc. - Rottapharm|Madaus - SK Chemicals Co., Ltd. - Synergy Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Takeda Pharmaceutical Company Limited - Tioga Pharmaceuticals, Inc. - X-BODY BioSciences, Inc. - Yuhan Corporation Drug Profiles: - ramosetron - ibodutant - linaclotide - rifaximin - asimadoline - dexloxiglumide - eluxadoline - rifaximin - tenapanor - linaclotide - plecanatide - solabegron hydrochloride - elobixibat - ONO-2952 - LX-1033 - ASP-7147 - (mosapride Bacillus subtilis Streptococcas feacium) - DSP-6952 - SKI-3246 - SYN-010 - linaclotide - larazotide acetate - DA-6886 - YH-12852 - mexiletine hydrochloride - MDT-006 - RQ-00202730 - PBI-1737 - RQ-00310941 - GIC-1001 For more information visit http://www.researchandmarkets.com/research/tq...able_bowel
SHAREHOLDER ALERT: Brower Piven Announces the Investigation of Furiex Pharmaceuticals, Inc. in Connection with the Proposed Sale of the Company to Forest Laboratories, Inc.
Business Wire - Mon May 05, 3:41PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Furiex Pharmaceuticals, Inc. ("Furiex" or the "Company"
(NasdaqGS: FURX) and other violations of state law by the board of directors of Furiex relating to the proposed buyout of the Company by Forest Laboratories, Inc. ("Forest" .
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of Furiex Pharmaceuticals, Inc. of Claims Against Board of Directors of Company in Connection With the Sale of the Company to Forest Laboratories, Inc. -- FURX
GlobeNewswire - Mon May 05, 9:39AM CDT
Levi & Korsinsky notifies investors of Furiex Pharmaceuticals, Inc. ("Furiex" or "the Company" (Nasdaq:FURX) of claims of breaches of fiduciary duty and other violations of state law against the board of directors of the Company in connection with the sale of the Company to Forest Laboratories, Inc. ("Forest" . A complaint was filed in Delaware state court.
Earnings Results, Acquisitions, Drug Designations, Dividend Authorizations, and Licensing Agreements - Analyst Notes on AstraZeneca, Furiex, GW, Techne and Agenus
PR Newswire - Mon May 05, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding AstraZeneca PLC (NYSE: AZN), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), GW Pharmaceuticals plc (NASDAQ: GWPH), Techne Corp. (NASDAQ: TECH) and Agenus Inc. (NASDAQ: AGEN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1869-100free.
This Week in Biotech: Merger Mania Continues
Sean Williams, The Motley Fool - Motley Fool - Sat May 03, 12:15PM CDT
With the SPDR S&P Biotech Index up 23% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
INVESTOR ALERT - FURIEX PHARMACEUTICALS, INC.: The Law Offices of Vincent Wong Investigates the Sale of Furiex Pharmaceuticals, Inc.
Business Wire - Fri May 02, 10:21AM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Furiex Pharmaceuticals, Inc. (NasdaqGS:FURX) ("Furiex" in connection with the sale of the Company to Forest Laboratories, Inc. ("Forest" .
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Furiex Pharmaceuticals, Inc. Buyout
Business Wire - Thu May 01, 2:37PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Furiex Pharmaceuticals, Inc. ("Furiex" or the "Company" (Nasdaq:FURX) relating to the proposed acquisition by Forest Laboratories, Inc.
Merger & Acquisition Updates, Quarterly Earnings Releases, and Clinical Trial Results - Analyst Notes on Allergan, Amgen, Furiex, Teva and Alexion
PR Newswire - Thu May 01, 8:00AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Amgen Inc. (NASDAQ: AMGN), Furiex Pharmaceuticals Inc. (NASDAQ: FURX), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1902-100free.
INVESTOR ALERT - FURIEX PHARMACEUTICALS, INC.: The Law Offices of Vincent Wong Investigates the Sale of Furiex Pharmaceuticals, Inc. -- FURX
PR Newswire - Wed Apr 30, 1:41PM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Furiex Pharmaceuticals, Inc. (NasdaqGS: FURX) ("Furiex" in connection with the sale of the Company to Forest Laboratories, Inc. ("Forest" .
Actavis Q1 Earnings Beat On Generic Cymbalta Surprise
at Investor's Business Daily - Wed Apr 30, 10:10AM CDT
Specialty drug giant Actavis (ACT) beat analyst Q1 estimates Wednesday, but the company warned that Q2 earnings will be lower due to new competition. Actavis stock was up 2.5% in morning trading on the stock market today, near 203. Earnings jumped...
Actavis Reporting Q1 Earnings Amid Merger Frenzy
at Investor's Business Daily - Tue Apr 29, 2:33PM CDT
Specialty-drug giant Actavis (ACT) is due to report another quarter of growth, before the market open Wednesday, as the IBD 50 stock continues to swell through acquisitions. Analysts polled by Thomson Reuters estimate Actavis made $3.24 a share in...
Forest Labs Beats Easily on 4Q Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 11:10AM CDT
Forest Labs (FRX) also announced its intention to acquire Furiex which will expand its gastrointestinal franchise.
Ryan & Maniskas, LLP Announces Investigation of Furiex Pharmaceuticals, Inc.
PR Newswire - Tue Apr 29, 9:35AM CDT
Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Furiex Pharmaceuticals, Inc. ("Furiex" or the "Company" (NASDAQ: FURX) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Forest Laboratories, Inc. in a transaction valued at approximately $1.1 billion.
Stock Market News for April 29, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 9:06AM CDT
Benchmarks finished Monday’s choppy run mostly higher as investor sentiment following new deals in the health care sector, positive pending home sales data and intense selling pressure on internet stocks
INVESTOR ALERT Levi & Korsinsky, LLP Announces Investigation of Furiex Pharmaceuticals, Inc. and Its Board of Directors In Connection With the Sale of the Company to Forest Laboratories, Inc. -- FURX
PR Newswire - Tue Apr 29, 9:02AM CDT
Levi & Korsinsky is investigating the Board of Directors of Furiex Pharmaceuticals, Inc. ("Furiex" or "the Company" (NasdaqGS: FURX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Forest Laboratories, Inc. ("Forest" .
Global Erectile Dysfunction Therapeutics Pipeline Review 2014 - Analysis of 16 Companies
M2 - Tue Apr 29, 8:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tkfwf9/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Erectile Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Erectile Dysfunction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Erectile Dysfunction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Erectile Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Sanofi - Suda Ltd - Acorda Therapeutics, Inc. - Chong Kun Dang Pharmaceutical Corp. - IntelGenx Corp. - Apricus Biosciences, Inc. - Palatin Technologies, Inc. - Yuhan Corporation - Futura Medical plc - Fabre-Kramer Pharmaceuticals, Inc. - Pharmicell Co., Ltd. - Aprogen, Inc. - Furiex Pharmaceuticals, Inc. - NanoForm Therapeutics Ltd. - Sagene Pharmaceuticals, Inc. - LondonPharma Ltd For more information visit http://www.researchandmarkets.com/research/tkfwf9/erectile
Furiex Pharmaceuticals (FURX) Surges: Stock Moves 28.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 8:21AM CDT
Furiex Pharmaceuticals, Inc. (FURX) was a big mover last session, as the company saw its shares rise by roughly 29% on the day.
Why Did Forest Laboratories Buy Furiex Pharmaceuticals?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Apr 29, 8:00AM CDT
Forest Laboratories has decided to get in on the recent M&A spree in health care with a $1.1 billion acquisition of Furiex Pharmaceuticals . That doesn't cover the total potential consideration, as Furiex shareholders could receive up to an...
Premature Ejaculation - Pipeline Review, H1 2014
M2 - Mon May 12, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c22w8w/premature) has announced the addition of the "Premature Ejaculation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Premature Ejaculation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Ejaculation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Premature Ejaculation - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Premature Ejaculation and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Premature Ejaculation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Premature Ejaculation pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Profiled: - Allergan, Inc. - Ampio Pharmaceuticals, Inc. - Dong-A Socio Holdings Co Ltd - Furiex Pharmaceuticals, Inc. - NeuroHealing Pharmaceuticals Inc. - Plethora Solutions Holdings plc - SK Chemicals Co., Ltd. Drug Profiles: - tramadol hydrochloride - (lidocaine prilocaine) - dapoxetine hydrochloride - onabotulinumtoxinA - DA-8031 - IX-01 - modafinil - NCE-405 - Small Molecule for Sexual Dysfunction For more information visit http://www.researchandmarkets.com/research/c22w8w/premature
Furiex Pharmaceuticals Reports First Quarter 2014 Financial Results
Business Wire - Wed May 07, 3:05PM CDT
--Royalty revenues of $6.4 million.
Irritable Bowel Syndrome - Pipeline Review, H1 2014: 29 Companies and 37 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/tqsgh4/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Alba Therapeutics Corporation - AlbireoPharma - Alfa Wassermann S.p.A - AltheRx Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Dainippon Sumitomo Pharma Co., Ltd. - Dong-A Socio Holdings Co Ltd - Drais Pharmaceuticals, Inc. - Furiex Pharmaceuticals, Inc. - GIcare Pharma Inc - Hanmi Pharmaceuticals, Co. Ltd. - ImmusanT, Inc. - Ironwood Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. - MicroDose Therapeutx, Inc. - Ono Pharmaceutical Co., Ltd. - ProMetic Life Sciences Inc. - Protagonist Therapeutics Inc. - RaQualia Pharma Inc. - Rottapharm|Madaus - SK Chemicals Co., Ltd. - Synergy Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Takeda Pharmaceutical Company Limited - Tioga Pharmaceuticals, Inc. - X-BODY BioSciences, Inc. - Yuhan Corporation Drug Profiles: - ramosetron - ibodutant - linaclotide - rifaximin - asimadoline - dexloxiglumide - eluxadoline - rifaximin - tenapanor - linaclotide - plecanatide - solabegron hydrochloride - elobixibat - ONO-2952 - LX-1033 - ASP-7147 - (mosapride Bacillus subtilis Streptococcas feacium) - DSP-6952 - SKI-3246 - SYN-010 - linaclotide - larazotide acetate - DA-6886 - YH-12852 - mexiletine hydrochloride - MDT-006 - RQ-00202730 - PBI-1737 - RQ-00310941 - GIC-1001 For more information visit http://www.researchandmarkets.com/research/tq...able_bowel
SHAREHOLDER ALERT: Brower Piven Announces the Investigation of Furiex Pharmaceuticals, Inc. in Connection with the Proposed Sale of the Company to Forest Laboratories, Inc.
Business Wire - Mon May 05, 3:41PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Furiex Pharmaceuticals, Inc. ("Furiex" or the "Company"
(NasdaqGS: FURX) and other violations of state law by the board of directors of Furiex relating to the proposed buyout of the Company by Forest Laboratories, Inc. ("Forest" . INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of Furiex Pharmaceuticals, Inc. of Claims Against Board of Directors of Company in Connection With the Sale of the Company to Forest Laboratories, Inc. -- FURX
GlobeNewswire - Mon May 05, 9:39AM CDT
Levi & Korsinsky notifies investors of Furiex Pharmaceuticals, Inc. ("Furiex" or "the Company"
(Nasdaq:FURX) of claims of breaches of fiduciary duty and other violations of state law against the board of directors of the Company in connection with the sale of the Company to Forest Laboratories, Inc. ("Forest" . A complaint was filed in Delaware state court. Earnings Results, Acquisitions, Drug Designations, Dividend Authorizations, and Licensing Agreements - Analyst Notes on AstraZeneca, Furiex, GW, Techne and Agenus
PR Newswire - Mon May 05, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding AstraZeneca PLC (NYSE: AZN), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), GW Pharmaceuticals plc (NASDAQ: GWPH), Techne Corp. (NASDAQ: TECH) and Agenus Inc. (NASDAQ: AGEN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1869-100free.
This Week in Biotech: Merger Mania Continues
Sean Williams, The Motley Fool - Motley Fool - Sat May 03, 12:15PM CDT
With the SPDR S&P Biotech Index up 23% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
INVESTOR ALERT - FURIEX PHARMACEUTICALS, INC.: The Law Offices of Vincent Wong Investigates the Sale of Furiex Pharmaceuticals, Inc.
Business Wire - Fri May 02, 10:21AM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Furiex Pharmaceuticals, Inc. (NasdaqGS:FURX) ("Furiex"
in connection with the sale of the Company to Forest Laboratories, Inc. ("Forest" . SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Furiex Pharmaceuticals, Inc. Buyout
Business Wire - Thu May 01, 2:37PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Furiex Pharmaceuticals, Inc. ("Furiex" or the "Company"
(Nasdaq:FURX) relating to the proposed acquisition by Forest Laboratories, Inc. Merger & Acquisition Updates, Quarterly Earnings Releases, and Clinical Trial Results - Analyst Notes on Allergan, Amgen, Furiex, Teva and Alexion
PR Newswire - Thu May 01, 8:00AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Amgen Inc. (NASDAQ: AMGN), Furiex Pharmaceuticals Inc. (NASDAQ: FURX), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1902-100free.
INVESTOR ALERT - FURIEX PHARMACEUTICALS, INC.: The Law Offices of Vincent Wong Investigates the Sale of Furiex Pharmaceuticals, Inc. -- FURX
PR Newswire - Wed Apr 30, 1:41PM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Furiex Pharmaceuticals, Inc. (NasdaqGS: FURX) ("Furiex"
in connection with the sale of the Company to Forest Laboratories, Inc. ("Forest" . Actavis Q1 Earnings Beat On Generic Cymbalta Surprise
at Investor's Business Daily - Wed Apr 30, 10:10AM CDT
Specialty drug giant Actavis (ACT) beat analyst Q1 estimates Wednesday, but the company warned that Q2 earnings will be lower due to new competition. Actavis stock was up 2.5% in morning trading on the stock market today, near 203. Earnings jumped...
Actavis Reporting Q1 Earnings Amid Merger Frenzy
at Investor's Business Daily - Tue Apr 29, 2:33PM CDT
Specialty-drug giant Actavis (ACT) is due to report another quarter of growth, before the market open Wednesday, as the IBD 50 stock continues to swell through acquisitions. Analysts polled by Thomson Reuters estimate Actavis made $3.24 a share in...
Forest Labs Beats Easily on 4Q Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 11:10AM CDT
Forest Labs (FRX) also announced its intention to acquire Furiex which will expand its gastrointestinal franchise.
Ryan & Maniskas, LLP Announces Investigation of Furiex Pharmaceuticals, Inc.
PR Newswire - Tue Apr 29, 9:35AM CDT
Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Furiex Pharmaceuticals, Inc. ("Furiex" or the "Company"
(NASDAQ: FURX) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Forest Laboratories, Inc. in a transaction valued at approximately $1.1 billion. Stock Market News for April 29, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 9:06AM CDT
Benchmarks finished Monday’s choppy run mostly higher as investor sentiment following new deals in the health care sector, positive pending home sales data and intense selling pressure on internet stocks
INVESTOR ALERT Levi & Korsinsky, LLP Announces Investigation of Furiex Pharmaceuticals, Inc. and Its Board of Directors In Connection With the Sale of the Company to Forest Laboratories, Inc. -- FURX
PR Newswire - Tue Apr 29, 9:02AM CDT
Levi & Korsinsky is investigating the Board of Directors of Furiex Pharmaceuticals, Inc. ("Furiex" or "the Company"
(NasdaqGS: FURX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Forest Laboratories, Inc. ("Forest" . Global Erectile Dysfunction Therapeutics Pipeline Review 2014 - Analysis of 16 Companies
M2 - Tue Apr 29, 8:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tkfwf9/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Erectile Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Erectile Dysfunction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Erectile Dysfunction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Erectile Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Sanofi - Suda Ltd - Acorda Therapeutics, Inc. - Chong Kun Dang Pharmaceutical Corp. - IntelGenx Corp. - Apricus Biosciences, Inc. - Palatin Technologies, Inc. - Yuhan Corporation - Futura Medical plc - Fabre-Kramer Pharmaceuticals, Inc. - Pharmicell Co., Ltd. - Aprogen, Inc. - Furiex Pharmaceuticals, Inc. - NanoForm Therapeutics Ltd. - Sagene Pharmaceuticals, Inc. - LondonPharma Ltd For more information visit http://www.researchandmarkets.com/research/tkfwf9/erectile
Furiex Pharmaceuticals (FURX) Surges: Stock Moves 28.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 8:21AM CDT
Furiex Pharmaceuticals, Inc. (FURX) was a big mover last session, as the company saw its shares rise by roughly 29% on the day.
Why Did Forest Laboratories Buy Furiex Pharmaceuticals?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Apr 29, 8:00AM CDT
Forest Laboratories has decided to get in on the recent M&A spree in health care with a $1.1 billion acquisition of Furiex Pharmaceuticals . That doesn't cover the total potential consideration, as Furiex shareholders could receive up to an...
